Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ATHE
ALTERITY THERAPEUTICS LIMITED
NASDAQ
$4.51
▼ DOWN 1.10% (-0.05)

KEY STATISTICS

Market Cap$76.40 M
52w High$5.89
52w Low$2.66
Dividend Yield—
Frequency—
P/E-5.76
Volume11.65K
Shares Out.16.94M

COMPANY

LEADERSHIP

David A. Stamler
CHIEF EXECUTIVE
David A. Stamler

ABOUT

SECTOR
Healthcare
WENT PUBLIC
September 29, 2003
METHOD OF GOING PUBLIC
Dual Listing
FULL TIME EMPLOYEES
9

PRICE TARGET

Target High$12.00
Target Low$2.00
Target Median$7.00
Target Consensus$7.00

UPCOMING EARNINGS

DateMar 4, 2027
DayThursday
Rev. Est.$1.20M
MAR
4
THU

SPLIT RECORD

DATETYPERATIO
2023-01-09Reverse1:10
2016-03-24Reverse1:6

PRICE

$4.51 ▼ DOWN 1.10% (−$0.05)
OVERLAYS
$4.45$4.50$4.55$4.609:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM4.51

About Alterity Therapeutics Limited

https://alteritytherapeutics.com ↗

Alterity Therapeutics Limited, based in Melbourne, develops drugs for neurological disorders like Alzheimer's, Parkinson's, and Huntington's, with lead candidates ATH434 and PBT2 having completed Phase I and IIa trials respectively.

INDUSTRY

Biotechnology

A PRODUCT ALTERITY THERAPEUTICS LIMITED IS KNOWN FOR

ATH434
ATH434

ATH434, Alterity Therapeutics' lead oral small molecule, aims to treat Multiple System Atrophy by redistributing brain iron to reduce α-synuclein aggregation, potentially serving as a first-in-class, disease-modifying therapy.

COMPETITORS

COMPETITOR
ACAD COMPARE
ANVS COMPARE
DNLI COMPARE
IKT COMPARE
PRTA COMPARE

INSTITUTIONAL OWNERSHIP

SHARES OWNED
2.40%
HOLDERS
30
TOP 12 OF 30 · RANKED BY POSITION SIZE
Twin Lakes Capital Management, LLC
139.3K sh · $747.82K
Morgan Stanley
68.7K sh · $258.24K
Greenleaf Trust
62.0K sh · $332.94K
Hb Wealth Management, LLC
58.5K sh · $219.81K
Citadel Advisors LLC
37.6K sh · $201.9K
Hrt Financial LP
17.3K sh · $92K
Bnp Paribas Arbitrage, Snc
10.2K sh · $54.98K
Acadian Asset Management LLC
4.8K sh · $14K
Advisor Group, Inc.
2.7K sh · $2K
Gamma Investing LLC
2.3K sh · $12.4K
Rhumbline Advisers
2.1K sh · $6.55K
Advantage Investment Management, LLC
1.1K sh · $1K

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book4
Overall Score2

INSIDER TRADES

★
DIRECTOR
Babarczy Julian Michael
Purchase · 2.0M shares
2026-06-15
★
DIRECTOR
Gozlan Lawrence Bernard
Purchase · 1.0M shares
2026-06-15
★
DIRECTOR:
Cunningham Ann Michelle
— · —
2026-04-17
★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Stamler David Allen
— · 40.0M shares
2026-04-15

SECTORS PEERS

PEERPRICE
ANVS$1.72COMPARE
DYAI$0.61COMPARE
EVAX$3.01COMPARE
LIMN$4.23COMPARE
BTAI$0.18COMPARE